Kathleen Mullin

Jul 3, 2024 | headachejournal.onlinelibrary.wiley.com | Richard Lipton |Jessica Ailani |Kathleen Mullin |Jelena M Pavlovic

CGRP calcitonin gene–related peptide MOH medication-overuse headache ODT orally disintegrating tablet INTRODUCTION A new class of medication for the acute and/or preventive treatment of migraine, the small molecule calcitonin gene–related peptide (CGRP) receptor antagonists (gepants), was introduced in the United States in 2019 and now includes four agents: rimegepant, ubrogepant, atogepant, and zavegepant.1 In addition to being the only drug class with medicines approved for the acute and...